SCHEMBL15076929

SCHEMBL15076929

Cc1nn(-c2ccnc(C(N)=O)c2)c(C)c1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.47
▸ POLB P06746 4/20 0.42
▸ RAB9A P51151 4/20 0.42
▸ MAPT P10636 3/20 0.42
▸ PDE4D Q08499 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ ALKBH1 Q13686 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ EGLN1 Q9GZT9 1/20 0.41
▸ NPC1 O15118 3/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ PIM1 P11309 1/20 0.40
▸ RCE1 Q9Y256 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15076927 0.86 LMNA (0.44) LMNAPOLBRAB9AMAPTPDE4D
SCHEMBL15076969 0.83 NPC1 (0.44) LMNAPOLBRAB9AMAPTPDE4D
SCHEMBL2938583 0.75 MEN1 (0.69) POLBRAB9AMAPTPDE4DL3MBTL1
SCHEMBL15072736 0.74 L3MBTL1 (0.49) POLBRAB9AMAPTL3MBTL1NPSR1
SCHEMBL6070720 0.74 PDE4D (0.68) LMNAPOLBRAB9AMAPTPDE4D
SCHEMBL2201331 0.73 LMNA (0.60) LMNAPOLBRAB9AMAPTL3MBTL1
SCHEMBL2201890 0.73 LMNA (0.64) LMNAPOLBRAB9AMAPTPDE4D
SCHEMBL27920237 0.72 KMT2A (0.63) LMNARAB9AMAPTPDE4DNPSR1
SCHEMBL2197832 0.72 EGLN1 (0.54) LMNAPOLBRAB9AMAPTPDE4D
SCHEMBL28524227 0.72 RAB9A (0.64) LMNAPOLBRAB9AMAPTPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165464-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165464-A1 HETEROARYLS AND USES THEREOF PIK3C2B, PI4KB, PIK3R4 LMNA 3432/4885POLB 282/4885RAB9A 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback